Lantheus Holdings (Lantheus Holdings) FCF Margin % : 28.31% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Lantheus Holdings's Free Cash Flow for the three months ended in Dec. 2023 was $100 Mil. Lantheus Holdings's Revenue for the three months ended in Dec. 2023 was $354 Mil. Therefore, Lantheus Holdings's FCF Margin % for the quarter that ended in Dec. 2023 was 28.31%.

As of today, Lantheus Holdings's current FCF Yield % is 5.76%.

The historical rank and industry rank for Lantheus Holdings's FCF Margin % or its related term are showing as below:

LNTH' s FCF Margin % Range Over the Past 10 Years
Min: 1.14 Med: 11.6 Max: 28.17
Current: 19.96

During the past 13 years, the highest FCF Margin % of Lantheus Holdings was 28.17%. The lowest was 1.14%. And the median was 11.60%.

LNTH's FCF Margin % is ranked better than
90.64% of 1026 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs LNTH: 19.96

Lantheus Holdings FCF Margin % Historical Data

The historical data trend for Lantheus Holdings's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings FCF Margin % Chart

Lantheus Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

16.79

1.16

9.82

28.17

19.96

Lantheus Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															38.24	33.02	-13.35	31.92	28.31

Competitive Comparison of Lantheus Holdings's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lantheus Holdings's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Lantheus Holdings's FCF Margin % falls into.

Lantheus Holdings FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Lantheus Holdings's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	258.705	/	1296.429
	=	19.96 %

Lantheus Holdings's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	100.218	/	353.999
	=	28.31 %

Lantheus Holdings FCF Margin % Related Terms

Thank you for viewing the detailed overview of Lantheus Holdings's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lantheus Holdings (Lantheus Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Executives

Andrea Sabens	officer: Chief Accounting Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Marshall Robert J. Jr.	officer: CFO and Treasurer	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Paul Blanchfield	officer: Chief Commercial Officer	C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
Mary Anne Heino	director, officer: CEO and President	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Daniel Niedzwiecki	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Sam R Leno	director	C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Brian A Markison	director	501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost	officer: Chief Medical Officer	C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Carol Walker	officer: Senior Vice President, Quality	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Ying Vivian Yao	officer: Chief Human Resources Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
John J. Bolla	director	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862